TriSalus publishes Pressure-Enabled Drug Delivery technology results

TriSalus Life Sciences (TLSI) announced the publication of clinical data evaluating the use of its proprietary Pressure-Enabled Drug Delivery technology in thyroid parenchymal embolization, a new application for the treatment of patients with symptomatic thyroid disease. Published in the Journal of the Endocrine Society, this retrospective single-center study by Gad et al. evaluated the safety, feasibility, and early efficacy of Pressure-Enabled Thyroid Artery Embolization using the TriNav Infusion System. This novel, minimally invasive technique targets the inferior thyroid arteries to reduce gland size and alleviate symptoms in patients who are not candidates for surgery or conventional therapies. 100% technical and clinical success. Overall, 71% of patients with hyperthyroidism achieved normal thyroid function; 73% mean reduction in thyroid gland volume at 6 months; no major complications or neurovascular events; mild post-procedure symptoms reported in 81% of patients, resolving within two weeks and no patients developed hypothyroidism following the procedure. The authors conclude that PED-TAE is a safe and feasible treatment option for large goiters and may offer an alternative to more invasive approaches for treating large benign thyroid nodules and benign multinodular goiters. However, prospective research is needed to establish long-term efficacy.